InsiderPulse
Dashboard

DGX

Quest Diagnostics Incorporated

Health CareS&P 500

Quest Diagnostics Incorporated insider trading

Every time one of DGX's executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

SEC Form 4 data, Q3 2024 to Q2 2026

DGX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 9 insiders traded DGX on the open market: 0 purchases and 81 sales worth $68.5M, 61 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 37 sales ($38.6M), by 8 insiders.

QuarterBoughtSold
Q2 2026—−$3.6M2 sales · all on a plan
Q1 2026—−$12.8M17 sales · 16 on a plan
Q4 2025—−$12.6M6 sales · 4 on a plan
Q3 2025—−$9.6M12 sales · all on a plan
Q2 2025—−$7.3M18 sales · all on a plan
Q1 2025—−$2.9M12 sales · 9 on a plan
Q4 2024—−$14.3M11 sales
Q3 2024—−$5.4M3 sales
Largest sale
−$7.9M of DGX by Davis J. E. (CEO and President · Director) on Nov 25, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Kuppusamy Karthik10b5-1

    SVP, Clinical Solutions

    −$1.6M

    Jun 04, 2026

    8,147 sh · $200.00

  • Davis J. E.10b5-1

    CEO and President · Director

    −$1.9M

    Jun 01, 2026

    10,000 sh · $194.14

  • Doherty Catherine T.10b5-1

    EVP, Regional Businesses

    −$1.1M

    Mar 05, 2026

    5,558 sh · $206.21

  • Prevoznik Michael E10b5-1

    SVP & General Counsel

    −$799.7K

    Mar 05, 2026

    3,878 sh · $206.21

  • Plewman Patrick10b5-1

    SVP for Diagnostic Services

    −$588.7K

    Mar 05, 2026

    2,855 sh · $206.21

  • Kuppusamy Karthik

    SVP, Clinical Solutions

    −$538.4K

    Mar 04, 2026

    2,628 sh · $204.86

  • Doherty Catherine T.10b5-1

    EVP, Regional Businesses

    −$131.3K

    Mar 03, 2026

    632 sh · $207.73

  • Prevoznik Michael E10b5-1

    SVP & General Counsel

    −$109.3K

    Mar 03, 2026

    526 sh · $207.73

  • Plewman Patrick10b5-1

    SVP for Diagnostic Services

    −$85.2K

    Mar 03, 2026

    410 sh · $207.73

  • Davis J. E.10b5-1

    CEO and President · Director

    −$2.1M

    Mar 02, 2026

    10,000 sh · $212.52

  • Doherty Catherine T.10b5-1

    EVP, Regional Businesses

    −$293.5K

    Feb 19, 2026

    1,433 sh · $204.83

  • Prevoznik Michael E10b5-1

    SVP & General Counsel

    −$227.6K

    Feb 19, 2026

    1,111 sh · $204.83

  • Plewman Patrick10b5-1

    SVP for Diagnostic Services

    −$196.2K

    Feb 19, 2026

    958 sh · $204.83

  • Doherty Catherine T.10b5-1

    EVP, Regional Businesses

    −$2.2M

    Feb 13, 2026

    10,573 sh · $205.21

  • Doherty Catherine T.10b5-1

    EVP, Regional Businesses

    −$2.1M

    Feb 13, 2026

    10,122 sh · $206.37

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

After insiders bought DGX

What the stock actually did in the 90 days following each open-market purchase

Don't check DGX — let it ping you

Get told the moment an insider moves on DGX

Pro watches Quest Diagnostics Incorporated for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add DGX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track DGX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read DGX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

RVTYSOLVSTEUHSWATLLYUNHJNJABBVMRKTMOABT
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

How much DGX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 9 Quest Diagnostics Incorporated insiders made no open-market purchases and 81 sales worth $68.5M. 61 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 37 sales ($38.6M). The largest sale was Davis J. E. selling $7.9M on Nov 25, 2025.
Where does DGX insider trading data come from?
From the Form 4 filings Quest Diagnostics Incorporated's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.